SynBioBeta Speaker
Rimma Boshernitsan
DIALOGUE
CEO, Futurist, Strategist
Rimma Boshernitsan is a futurist, strategist, and the founder and CEO of DIALOGUE, an interdisciplinary strategic advisory that helps leaders stop reacting to the zeitgeist—and start shaping it. Over the course of a 20-year career, she has served as a strategic advisor and thought partner to CEOs of emerging businesses and Fortune 500 organizations, including Apple, Tata, Roche, Google, Kaiser Permanente, Aesop, Levi’s, Lyft, Kraft Foods, and Chevron. She has worked internationally, including in Moscow, London, and throughout the U.S.Rimma began her career at Deloitte Consulting’s Human Capital practice, where she focused on M&A and large-scale transformation, before moving into in-house advisory work across healthcare, consumer business, and telecommunications. A period advising contemporary art collectors sharpened her sensitivity to how cultural, political, and scientific shifts often emerge at the edges of institutions before becoming strategic imperatives within them. That insight led her to found DIALOGUE.At the center of Rimma’s work is a model she calls the Triad of Intelligences: human intelligence, machine intelligence, and planetary intelligence. Her work on co-intelligence is not in biotech itself, but adjacent and highly relevant to it—focused on how societies, institutions, and leaders make wiser decisions about health, healthspan, longevity, and the conditions that allow life to flourish. She explores how human intuition, ethical judgment, and living systems awareness must evolve alongside technical capability if innovation is to remain coherent, evidence-based, and humane. In her recent work, including her Noema essay and talks on a planetary nervous system, she argues that health is not only a clinical question, but a systems question.  Rimma’s expertise moves across strategic foresight, AI transformation, and co-intelligent leadership. She has spoken and moderated at SXSW, the Swiss Consulate, WRLDCTY, and other public forums, and is known for guiding conversations that connect frontier innovation to its broader human, ethical, and societal implications. At SynBioBeta, she brings an interdisciplinary lens to the frontier of longevity science—focused less on the lab itself than on the larger questions of judgment, coherence, healthspan, and human consequence that emerge around it.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Rimma
This Year
•
-
Human Health
Epigenetics and Stem Cells reprogramming / evidence based longevity
Aging is not a destiny. It is a program. And programs can be rewritten.Epigenetic clocks are now precise enough to measure biological age down to the tissue level. Stem cell engineering is restoring function in systems once thought irreversible. Longevity science — for the first time in its history — has the tools to match its ambitions.This chamber convenes the researchers doing the matching: scientists who have moved past the supplement stacks and the headlines, into the hard, exacting work of understanding what drives cellular aging — and what, with enough precision, can slow it, reverse it, or render it beside the point.
•
-
Human Health
Epigenetics and Stem Cells reprogramming / evidence based longevity
Aging is not a destiny. It is a program. And programs can be rewritten.Epigenetic clocks are now precise enough to measure biological age down to the tissue level. Stem cell engineering is restoring function in systems once thought irreversible. Longevity science — for the first time in its history — has the tools to match its ambitions.This chamber convenes the researchers doing the matching: scientists who have moved past the supplement stacks and the headlines, into the hard, exacting work of understanding what drives cellular aging — and what, with enough precision, can slow it, reverse it, or render it beside the point.
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
